Skip to main content

2023 Editor's Highlights

With great satisfaction we can be proud to state that our journal, Cardiovascular Diabetology, has succeeded in increasing its status during 2023 as one of the world’s leading journals in the areas it encompasses. The journal is currently positioned in the 88.7 and 93.1 percentiles of academic publications in the Journal Citation Reports categories "Cardiac & Cardiovascular Systems” and “Endocrinology & Metabolism”, respectively. These figures represent an increase compared to 2022 and in addition, its 2-year Journal Impact Factor – generally considered as the most important index of scholar prestige - has risen to 9.3.

Another relevant achievement is that our journal – despite its high rejection rate - published 353 articles in 2023, the largest quantity in its history. It is important to emphasize this point because over the last few years countless open access journals have been launched and the competition between them has increased substantially. Unfortunately, many of these new periodicals are predatory medical journals which lack a serious peer-review process, offer quick publication, and usually attract low-quality manuscripts; part of them may be fraudulent. The business model of these predatory journals is based on a relatively low APC to be paid by the authors. Thus, in our “publish or perish” current academic culture this can be tempting for authors who are not aware of the existence of dubious or even unscrupulous publishers that may endanger public health and scientific credibility. In this context, Cardiovascular Diabetology is committed to supporting research integrity and maintaining its high standard and rigorous single-blind peer-review model.

A fundamental aspect of the changes that have occurred in 2023 is the considerable increase in our editorial staff. Cardiovascular Diabetology currently has an Editor-in-Chief, a Deputy Editor, nearly sixty Associate Editors and thirty members of the Editorial Board. This ample workforce makes it easier to handle a great number of manuscripts in a shorter turnaround time, assigning each article to editors specialized in the specific paper’s area and enhancing the flexibility of the review process. The knowledge and copious experience of the Associate Editors enhance the scientific level of Cardiovascular Diabetology. This fact, as well as Springer Nature biomedicine publisher Victoria Hentschke's efficient work and initiatives contribute enormously to the successful accomplishment of the journal’s tasks.

The main thematic preferences of the articles submitted to our journal have been rather similar to those of last year, including

  • ​​​​​​​​​​​​​​Inflammation in cardiometabolic diseases, 
  • diagnostic and prognostic importance of the triglyceride glucose index in several clinical settings,
  • machine learning, 
  • biomarkers, 
  • novel antidiabetic pharmacotherapy (gliflozins and incretin mimetic compounds), 
  • type 1 diabetes,
  • percutaneous coronary interventions in diabetic patients,
  • obesity,
  • lipidology,
  • treatment of heart failure,
  • influence of anthropometric measurements on the development of cardiometabolic diseases,
  • epicardial fat thickness,
  • proteomics,
  • gender-specific differences and 
  • epidemiology

The preceding paragraphs constitute just a comprehensive summary focusing on the recent development and impact of our journal. Here, we would like to offer you a selection of some of 2023 most relevant articles.

Prof. Enrique Fisman, MD
Cardiovascular Diabetology
Co-founder and Editor-in-Chief

SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, Cosimo Sacra, Gerardo Carpinella, Ciro Mauro, Fabio Minicucci, Paolo Calabrò, Michele D’ Amico, Fabrizio D’ Ascenzo, Ovidio De Filippo, Mario Iannaccone, Carmine Pizzi, Giuseppe Paolisso & Raffaele Marfella

Research | Published: 01 April 2023

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms

Keming Huang, Xianling Luo, Bin Liao, Guang Li & Jian Feng

Review | Published: 13 April 2023

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial

Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad & Signe S. Torekov

Research | Published: 25 February 2023

Cardiovascular complications in a diabetes prediction model using machine learning: a systematic review

Ooi Ting Kee, Harmiza Harun, Norlaila Mustafa, Nor Azian Abdul Murad, Siok Fong Chin, Rosmina Jaafar & Noraidatulakma Abdullah

Review | Published: 19 January 2023

Impaired insulin-stimulated myocardial glucose metabolic rate is associated with reduced estimated myocardial energetic efficiency in subjects with different degrees of glucose tolerance

Elena Succurro, Francesco Cicone, Annalisa Papa, Sofia Miceli, Patrizia Vizza, Teresa Vanessa Fiorentino, Maria Perticone, Angela Sciacqua, Pietro Hiram Guzzi, Pierangelo Veltri, Giuseppe Lucio Cascini, Francesco Andreozzi & Giorgio Sesti

Research | Published: 09 January 2023

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors

Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, Ada Pesapane, Surina, Vittoria Cataldo, Puja Ghosh, Martina Franzese, Armando Puocci, Pasquale Paolisso, Concetta Rafaniello, Raffaele Marfella, Maria Rosaria Rizzo, Emanuele Barbato, Marc Vanderheyden & Michelangela Barbieri

Research | Published: 02 February 2023

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Pierre Gourdy, Patrice Darmon, François Dievart, Jean-Michel Halimi & Bruno Guerci

Review | Published: 01 April 2023

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease

Toshiyuki Nishikido

Review | Published: 30 January 2023

Machine learning in precision diabetes care and cardiovascular risk prediction

Evangelos K. Oikonomou & Rohan Khera

Review | Published: 25 September 2023

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

Sara Piccini, Giuseppe Favacchio, Cristina Panico, Emanuela Morenghi, Franco Folli, Gherardo Mazziotti, Andrea Gerardo Lania & Marco Mirani

Research | Published: 25 March 2023

The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy

Santosh K Sanganalmath, Shubham Dubey, Sudhakar Veeranki, Keerthy Narisetty & Prasanna Krishnamurthy

Review | Published: 20 February 2023

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Adam Goldman, Boris Fishman, Gilad Twig, Emanuel Raschi, Tali Cukierman-Yaffe, Yonatan moshkovits, Alon Pomerantz, Ilan Ben-Zvi, Rachel Dankner & Elad Maor

Research | Published: 24 January 2023

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction

Ulrich Kintscher & Frank Edelmann

Review | Published: 29 June 2023

Maternal obesity and gestational diabetes reprogram the methylome of offspring beyond birth by inducing epigenetic signatures in metabolic and developmental pathways

Juan José Alba-Linares, Raúl F. Pérez, Juan Ramón Tejedor, David Bastante-Rodríguez, Francisco Ponce, Nuria García Carbonell, Rafael Gómez Zafra, Agustín F. Fernández, Mario F. Fraga & Empar Lurbe

Research | Published: 04 March 2023

Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4+ T cells

Narmadha Subramanian, Kaisa Hofwimmer, Beatriz Tavira, Lucas Massier, Daniel P Andersson, Peter Arner & Jurga Laurencikiene

Research | Published: 12 April 2023

L-Arginine in diabetes: clinical and preclinical evidence

Imma Forzano, Roberta Avvisato, Fahimeh Varzideh, Stanislovas S. Jankauskas, Angelo Cioppa, Pasquale Mone, Luigi Salemme, Urna Kansakar, Tullio Tesorio, Valentina Trimarco & Gaetano Santulli

Review | Published: 18 April 2023

Genetic deletion of hepatic NCOR1 protects from atherosclerosis by promoting alternative bile acid-metabolism and sterol excretion

Martin Geiger, Sara Oppi, Stefanie Nusser-Stein, Sarah Costantino, Shafeeq Ahmed Mohammed, Era Gorica, Joanne A. Hoogerland, Christian M. Matter, Ana T. Guillaumon, Frank Ruschitzka, Francesco Paneni, Maaike H. Oosterveer & Sokrates Stein

Research | Published: 22 June 2023

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

Minji Sohn, Johannes W. Dietrich, Michael A. Nauck & Soo Lim

Research | Published: 28 June 2023

Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE Registry, a large observational study

Yasuo Terauchi, Hiroshi Inoue, Takeshi Yamashita, Masaharu Akao, Hirotsugu Atarashi, Takanori Ikeda, Yukihiro Koretsune, Ken Okumura, Shinya Suzuki, Hiroyuki Tsutsui, Kazunori Toyoda, Atsushi Hirayama, Masahiro Yasaka, Takenori Yamaguchi, Satoshi Teramukai, Tetsuya Kimura, Yoshiyuki Morishima, Atsushi Takita & Wataru Shimizu

Research | Published: 12 July 2023

The cardio-renal-metabolic connection: a review of the evidence

Marella Marassi & Gian Paolo Fadini

Review | Published: 31 July 2023

An innovative model for predicting coronary heart disease using triglyceride-glucose index: a machine learning-based cohort study

Seyed Reza Mirjalili, Sepideh Soltani, Zahra Heidari Meybodi, Pedro Marques-Vidal, Alexander Kraemer & Mohammadtaghi Sarebanhassanabadi

Research | Published: 04 August 2023

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Yue Gu, Elisa Avolio, Valeria V Alvino, Anita C Thomas, Andrew Herman, Poppy J Miller, Niall Sullivan, Ashton Faulkner & Paolo Madeddu

Research | Published: 17 August 2023

Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40–65: a prospective cross-sectional study

Chong-Yu Zhang, Ru-Qin Xu, Xiao-Qiao Wang, Lin-Feng Sun, Pei Mo, Ren-Jie Cai, Xiao-Zhen Lin, Cheng-Feng Luo, Wen-Chao Ou, Lie-Jing Lu, Yun Zhong & Jia-Yuan Chen

Research | Published: 24 August 2023

Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: the Hoorn Diabetes Care System Cohort

Elisa Dal Canto, L. van Deursen, A. G. Hoek, P. J. M. Elders, H. M. den Ruijter, J. van der Velden, V. van Empel, E. H. Serné, E. C. Eringa & J. W.J. Beulens

Research | Published: 01 September 2023

Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease

Juan Moreno-Vedia, Dídac Llop, Ricardo Rodríguez-Calvo, Núria Plana, Núria Amigó, Roser Rosales, Yaiza Esteban, Josefa Girona, Lluís Masana & Daiana Ibarretxe

Research | Published: 14 September 2023

Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project

Katarzyna Nabrdalik, Hanna Kwiendacz, Krzysztof Irlik, Mirela Hendel, Karolina Drożdż, Agata M. Wijata, Jakub Nalepa, Oliwia Janota, Wiktoria Wójcik, Janusz Gumprecht & Gregory Y. H. Lip

Research | Published: 20 November 2023

Genetic deletion of MMP12 ameliorates cardiometabolic disease by improving insulin sensitivity, systemic inflammation, and atherosclerotic features in mice

Melina Amor, Valentina Bianco, Martin Buerger, Margarete Lechleitner, Nemanja Vujić, Anja Dobrijević, Alena Akhmetshina, Anita Pirchheim, Birgit Schwarz, Ariane R. Pessentheiner, Franziska Baumgartner, Katharina Rampitsch, Silvia Schauer, Iva Klobučar, Vesna Degoricija, Gudrun Pregartner, Daniel Kummer, Monika Svecla, Gerhard Sommer, Dagmar Kolb, Gerhard A. Holzapfel, Gerald Hoefler, Saša Frank, Giuseppe Danilo Norata & Dagmar Kratky

Research | Published: 28 November 2023

Isthmin-1 (ISM1), a novel adipokine that reflects abdominal adipose tissue distribution in individuals with obesity

Marta Lopez-Yus, Carmen Casamayor, Juan Jose Soriano-Godes, Sofia Borlan, Yolanda Gonzalez-Irazabal, Maria Pilar Garcia-Sobreviela, Beatriz Garcia-Rodriguez, Raquel del Moral-Bergos, Pilar Calmarza, Jose Maria Artigas, Silvia Lorente-Cebrian, Vanesa Bernal-Monterde, Alejandro Sanz-Paris & Jose M. Arbones-Mainar

Research | Published: 08 December 2023

Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study

Tracey G. Simon, Fahim Ebrahimi, Bjorn Roelstraete, Hannes Hagström, Johan Sundström & Jonas F. Ludvigsson

Research | Published: 13 December 2023

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

Francesca Cinti, Lucia Leccisotti, Gian Pio Sorice, Umberto Capece, Domenico D’Amario, Margherita Lorusso, Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Maria Angela Guzzardi, Teresa Mezza, Amedeo Capotosti, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano & Andrea Giaccari

Research | Published: 19 December 2023

Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

Josep Iglesies-Grau, Ana Garcia-Alvarez, Belén Oliva, Guiomar Mendieta, Inés García-Lunar, José J. Fuster, Ana Devesa, Cristina Pérez-Herreras, Antonio Fernández-Ortiz, Ramon Brugada, Borja Ibanez, Rodrigo Fernandez-Jimenez & Valentin Fuster

Research | Published: 19 December 2023

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2022 Speed
    3 days submission to first editorial decision for all manuscripts (Median)
    55 days submission to accept (Median)

    2022 Usage 
    14,109 Altmetric mentions